4.8 Article

The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes

Journal

ONCOGENE
Volume 35, Issue 27, Pages 3485-3494

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2015.408

Keywords

-

Funding

  1. Spanish Government [SAF2012-32117]
  2. Instituto de Salud Carlos III [PI13/00132, RETIC-RD12/0036/0007]
  3. Regional Government of Madrid [S2010/BMD-2303]
  4. Spanish Government FPI program
  5. MRC [MC_U120085810] Funding Source: UKRI
  6. Medical Research Council [MC_U120085810] Funding Source: researchfish

Ask authors/readers for more resources

Cellular senescence is an antiproliferative response with essential functions in tumor suppression and tissue homeostasis. Here we show that SIX1, a member of the SIX family of homeobox transcriptional factors, is a novel repressor of senescence. Our data show that SIX1 is specifically downregulated in fibroblasts upon oncogenic stress and other pro-senescence stimuli, as well as in senescent skin premalignant lesions. Silencing of SIX1 in human fibroblasts suffices to trigger senescence, which is mediated by p16INK4A and lacks a canonical senescence-associated secretory phenotype. Interestingly, SIX1-associated senescence is further characterized by the expression of a set of development and differentiation-related genes that significantly overlap with genes associated with SIX1 in organogenesis or human tumors, and show coincident regulation in oncogene-induced senescence. Mechanistically, we show that gene regulation by SIX1 during senescence is mediated, at least in part, by cooperation with Polycomb repressive complexes. In summary, our results identify SIX1, a key development regulator altered in human tumors, as a critical repressor of cellular senescence, providing a novel connection between senescence, differentiation and tumorigenesis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

A. Fernandez Montes, E. Elez, A. Vivancos, N. Martinez, P. Gonzalez, M. Covela, J. de la Camara, A. Cousillas, J. C. Mendez, B. Grana, E. Aranda

Summary: A study found that 13% of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment, but some discrepancies between solid and liquid biopsies were observed. The results suggest a need to improve the accuracy of RAS analyses, especially in solid biopsies.

CLINICAL & TRANSLATIONAL ONCOLOGY (2022)

Article Oncology

ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma

Helena Verdaguer, Tamara Sauri, Daniel Alejandro Acosta, Magdalena Guardiola, Alexandre Sierra, Jorge Hernando, Paulo Nuciforo, Josep M. Miquel, Cristina Molero, Sandra Peiro, Queralt Serra-Camprubi, Guillermo Villacampa, Susana Aguilar, Ana Vivancos, Josep Tabernero, Rodrigo Dienstmann, Teresa Macarulla

Summary: Cholangiocarcinomas are highly heterogeneous at the molecular level. The classification of actionable molecular alterations according to ESCAT is associated with survival in cholangiocarcinoma patients.

CLINICAL CANCER RESEARCH (2022)

Article Biochemistry & Molecular Biology

Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression

Alba Mota, Sara S. Oltra, Pier Selenica, Cristian P. Moiola, Carlos Casas-Arozamena, Carlos Lopez-Gil, Eva Diaz, Sonia Gatius, Maria Ruiz-Miro, Ana Calvo, Alejandro Rojo-Sebastian, Pablo Hurtado, Roberto Pineiro, Eva Colas, Antonio Gil-Moreno, Jorge S. Reis-Filho, Laura Muinelo-Romay, Miguel Abal, Xavier Matias-Guiu, Britta Weigelt, Gema Moreno-Bueno

Summary: Analyzing intratumor genetic heterogeneity (ITGH) in endometrial carcinoma (EC) using sequencing technologies can help understand tumor evolution, prognosis, and guide personalized therapy. This study characterized the spatial and temporal heterogeneity of nine ECs and identified somatic mutations through whole-exome sequencing. The phylogenetic tree analysis revealed the correlation between tumor progression, prognosis, and recurrent disease, and also guided the selection of personalized therapy for a patient with ambiguous EC.

ONCOGENE (2022)

Article Cell Biology

Multi-omic rejuvenation of naturally aged tissues by a single cycle of transient reprogramming

Dafni Chondronasiou, Diljeet Gill, Lluc Mosteiro, Rocio G. Urdinguio, Antonio Berenguer, Monica Aguilera, Sylvere Durand, Fanny Aprahamian, Nitharsshini Nirmalathasan, Maria Abad, Daniel E. Martin-Herranz, Camille Stephan Otto-Attolini, Neus Prats, Guido Kroemer, Mario F. Fraga, Wolf Reik, Manuel Serrano

Summary: A single period of OSKM expression can induce epigenetic, transcriptomic, and metabolomic changes towards a younger configuration in multiple tissues.

AGING CELL (2022)

Article Cell Biology

Dynamic regulation of myofibroblast phenotype in cellular senescence

Irene Lopez-Antona, Constanza Contreras-Jurado, Laura Luque-Martin, Antonio Carpintero-Leyva, Paula Gonzalez-Mendez, Ignacio Palmero

Summary: Cellular senescence has a significant impact on the regulation of the myofibroblastic phenotype in primary fibroblasts. The loss of myofibroblastic markers and functional features upon senescence implementation can be transmitted in a paracrine manner, most likely through soluble secreted factors. The Notch/TGF-beta axis is found to be the main pathway mediating the changes in the myofibroblast phenotype.

AGING CELL (2022)

Article Gastroenterology & Hepatology

Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma

Marta Alonso-Nocelo, Laura Ruiz-Canas, Patricia Sancho, Kivanc Gorgulu, Sonia Alcala, Coral Pedrero, Mireia Vallespinos, Juan Carlos Lopez-Gil, Marina Ochando, Elena Garcia-Garcia, Sara Maria David Trabulo, Paola Martinelli, Patricia Sanchez-Tomero, Carmen Sanchez-Palomo, Patricia Gonzalez-Santamaria, Lourdes Yuste, Sonja Maria Wormann, Derya Kabacaoglu, Julie Earl, Alberto Martin, Fernando Salvador, Sandra Valle, Laura Martin-Hijano, Alfredo Carrato, Mert Erkan, Laura Garcia-Bermejo, Patrick C. Hermann, Hana Algul, Gema Moreno-Bueno, Christopher Heeschen, Francisco Portillo, Amparo Cano, Bruno Sainz

Summary: LOXL2 plays an important role in pancreatic ductal adenocarcinoma (PDAC), with its loss inhibiting metastasis and prolonging overall survival, while overexpression promotes tumor growth and decreases overall survival. Macrophage-secreted OSM is an inducer of LOXL2 expression, with targeting macrophages affecting its expression and collagen fiber alignment.
Editorial Material Neurosciences

Editorial: The Role of Cellular Senescence in Health and Disease

Ignacio Palmero, Vassilis Gorgoulis, Isabel Varela-Nieto

FRONTIERS IN CELLULAR NEUROSCIENCE (2022)

Article Oncology

Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

Ines Marin, Olga Boix, Andrea Garcia-Garijo, Isabelle Sirois, Adria Caballe, Eduardo Zarzuela, Irene Ruano, Camille Stephan-Otto Attolini, Neus Prats, Jose A. Lopez-Dominguez, Marta Kovatcheva, Elena Garralda, Javier Munoz, Etienne Caron, Maria Abad, Alena Gros, Federico Pietrocola, Manuel Serrano

Summary: Senescent cells possess various features that make them highly efficient in stimulating dendritic cells and antigen-specific CD8 T cells, including the release of alarmins, activation of IFN signaling, enhanced MHC class I machinery, and presentation of specific self-peptides. Immunization with senescent cancer cells induces strong antitumor protection mediated by DCs and CD8 T cells, surpassing the effectiveness of immunization with cancer cells undergoing immunogenic cell death. Furthermore, induction of senescence in human primary cancer cells enhances their ability to activate autologous antigen-specific tumor-infiltrating CD8 lymphocytes. This study highlights the potential of exploiting senescent cancer cells to develop efficient and protective CD8-dependent antitumor immune responses.

CANCER DISCOVERY (2023)

Article Multidisciplinary Sciences

pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activation

Olga Boix, Marion Martinez, Santiago Vidal, Marta Gimenez-Alejandre, Lluis Palenzuela, Laura Lorenzo-Sanz, Laura Quevedo, Olivier Moscoso, Jorge Ruiz-Orera, Pilar Ximenez-Embun, Nikaoly Ciriaco, Paolo Nuciforo, Camille Stephan-Otto Attolini, M. Mar Alba, Javier Munoz, Tian V. Tian, Ignacio Varela, Ana Vivancos, Santiago Ramon Cajal, Purificacion Munoz, Carmen Rivas, Maria Abad

Summary: The human transcriptome contains small open reading frames (sORFs) that encode microproteins with largely unexplored functions. In this study, the authors show that TINCR lncRNA encodes a ubiquitin-like protein (UBL) called pTINCR, which is expressed in many epithelia and promotes epithelial differentiation through the SUMOylation and activation of CDC42. They also found that low expression of TINCR is associated with worse prognosis in several epithelial cancers.

NATURE COMMUNICATIONS (2022)

Article Developmental Biology

Dysfunction of programmed embryo senescence is linked to genetic developmental defects

Cristina de Lope, Rebeca Garcia-Lucena, Marta Magarinos, Yolanda Leon, Nuria Casa-Rodriguez, Nuria Contreras, Carmen Escudero-Iriarte, Isabel Varela-Nieto, Pascal Maire, Ignacio Palmero

Summary: Developmental senescence, a type of programmed senescence, plays a role in embryonic morphogenesis. The SIX1 homeoprotein, known for its role in organogenesis, is also found to repress adult cellular senescence. Dysfunction of senescence may be connected to the developmental defects associated with SIX1 deficiency, as shown by studies on Six1-deficient mice. The aberrant senescence and altered morphogenesis in the inner ear of Six1-deficient mice suggests a link between senescence and disease through deregulation of the TGF beta/BMP pathway.

DEVELOPMENT (2023)

Article Immunology

Thyroid cells from normal and autoimmune thyroid glands suppress T lymphocytes proliferation upon contact revealing a new regulatory inhibitory type of interaction independent of PD1/PDL1

Daniel Alvarez-Sierra, Nerea Sanchez-Gaona, Maria Cruz Cobo, Alba Escriche, Maria Abad, Aroa Gomez-Brey, Irene Bello, Enric Caubet, Oscar Gonzalez, Carles Zafon, Carmela Iglesias, Pablo Moreno, Anna Petitj, Marco Antonio Fernandez-Sanmartin, Monica Martinez-Gallo, Ricardo Pujol-Borrell

Summary: Immune Checkpoint Receptors play a role in regulating immune responses and preventing tissue damage. Inhibiting the PD-1/PD-L1 receptor axis has shown promising results in cancer immunotherapy but can also lead to autoimmune adverse effects. This study investigates the role of PD-1/PD-L1 in the interaction between T cells and thyroid cells, and suggests that TFCs suppress T cell proliferation through the expansion of DN T cells, rather than PD-1/PD-L1. These findings contribute to our understanding of immune regulation and suggest alternative pathways for tumor evasion.

JOURNAL OF AUTOIMMUNITY (2023)

Article Oncology

Evaluation of ERBB2 mRNA Expression in HER2-Equivocal (2+) Immunohistochemistry Cases

Irene Carretero-Barrio, Tamara Caniego-Casas, Marta Rosas, Maria Concepcion Sanchez, Noelia Martinez-Janez, Miguel Chiva, David Sarrio, Gema Moreno-Bueno, Jose Palacios, Belen Perez-Mies

Summary: HER2-equivocal cases represent around 15% of breast carcinomas, and 20-40% of them are HER2-amplified. The evaluation of HER2 amplification status in equivocal cases is crucial for patient management. In this study, we investigated the performance of STRAT4, a RT-qPCR platform, compared to the recommended methods for the evaluation of HER2-equivocal cases. The results showed that STRAT4 is not reliable for the assessment of HER2 amplification status in equivocal cases.

CANCERS (2023)

Article Cell Biology

The E1a Adenoviral Gene Upregulates the Yamanaka Factors to Induce Partial Cellular Reprogramming

Gracia Mendoza, Rebeca Gonzalez-Pastor, Juan Miguel Sanchez, Altamira Arce-Cerezo, Miguel Quintanilla, Gema Moreno-Bueno, Anna Pujol, Carolina Belmar-Lopez, Alba de Martino, Efren Riu, Tristan A. Rodriguez, Pilar Martin-Duque

Summary: The induction of pluripotency can be achieved by enforced expression of different gene combinations in somatic cells. A previous report showed that the adenoviral E1a gene can induce the expression of two Yamanaka factors and epigenetic changes. In this study, the over-expression of E1a-12S was found to be sufficient to induce pluripotent-like characteristics in mouse embryonic fibroblasts through the activation of the pluripotency gene regulatory network. These findings provide empirical evidence for partial reprogramming with a single factor and a potential mechanistic explanation for viral-induced neoplasia.

CELLS (2023)

Article Biochemistry & Molecular Biology

RAGE/SNAIL1 signaling drives epithelial-mesenchymal plasticity in metastatic triple-negative breast cancer

Mireia Pujals, Carla Mayans, Chiara Bellio, Olga Mendez, Emanuela Greco, Roberta Fasani, Merce Alemany-Chavarria, Esther Zamora, Laura Padilla, Francesc Mitjans, Paolo Nuciforo, Francesc Canals, Lara Nonell, Maria Abad, Cristina Saura, Josep Tabernero, Josep Villanueva

Summary: Epithelial/mesenchymal (E/M) plasticity is important in both embryogenesis and tumorigenesis. The role of receptor for advanced glycation end products (RAGE) in triple-negative breast cancer (TNBC) is unclear. This study shows that RAGE signaling maintains the mesenchymal phenotype of aggressive TNBC cells through the expression of SNAIL1 and its crosstalk with the TGF-β pathway. RAGE inhibition promotes epithelial features and reduces migration and invasion capacities. In vivo inhibition of RAGE reduces metastasis incidence and improves survival.

ONCOGENE (2023)

Article Oncology

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Markus Jonsson, Ali Razzak, Irene Brana, Luigi De Petris, Jeffrey Yachnin, Richard D. Baird, Yohann Loriot, Christophe Massard, Patricia Martin-Romano, Frans Opdam, Richard F. Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Judith Balmana, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Frohling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile Voest, Jordi Rodon, Janne Lehtio

Summary: This article presents the implementation of the Molecular Tumor Board Portal, a system that integrates and interprets genomics and clinical data to support clinical decision-making in precision oncology. The system automates the interpretation and reporting of sequencing results, reducing errors and promoting consistent decision-making and data capture. It also facilitates collaborative discussion through information-rich patient reports and interactive content.

NATURE CANCER (2022)

No Data Available